慢性呼吸系统疾病药物福多司坦衍生物的设计、合成及活性评价

doi:10.6023/cjoc202409029

有机化学 ›› 2025, Vol. 45 ›› Issue (7): 2566-2576.DOI: 10.6023/cjoc202409029 上一篇下一篇

研究论文

慢性呼吸系统疾病药物福多司坦衍生物的设计、合成及活性评价

孙茂茹^a, 桂腾摇^a, 陈聪地^b, 杨鸿均^a^,^*(), 李雪锋^a

^a 西南民族大学化学与环境学院国家民委基础化学重点实验室成都 610041
^b 成都师范学院化学与生命科学学院成都 611130

收稿日期:2024-11-05 修回日期:2024-12-03 发布日期:2025-01-10
通讯作者: 杨鸿均
基金资助:
四川省功能分子结构优化与应用重点实验室（成都师范学院）(2023GNFZ-05); 西南民族大学中央高校优秀学生培养(320022350036)

Design, Synthesis, and Activity Assessment of Fudosteine Derivatives for Chronic Respiratory Disorders

Maoru Sun^a, Tengyao Gui^a, Congdi Chen^b, Hongjun Yang^a^,^*(), Xuefeng Li^a

^a Key Laboratory of General Chemistry of the National Ethnic Affairs Commission, School of Chemistry and Environment, Southwest Minzu University, Chengdu 610041
^b College of Chemistry and Life Science, Chengdu Normal University, Chengdu 611130

Received:2024-11-05 Revised:2024-12-03 Published:2025-01-10
Contact: Hongjun Yang
Supported by:
Sichuan Provincial Key Laboratory for Structural Optimization and Application of Functional Molecules, Chengdu Normal University(2023GNFZ-05); Southwest University for Nationalities Central University Excellent Student Training Project(320022350036)

文章分享

1. 附件.pdf(5456KB)

摘要/Abstract

慢性阻塞性肺疾病(慢阻肺, chronic obstructive pulmonary disease, COPD)由于其持续的症状影响患者的生活质量而受到越来越多的关注. 福多司坦治疗COPD的显著优势体现在其高疗效和低副作用. 本研究设计并合成了Fudosteine磺酰胺类衍生物系列Ⅰ和胺类衍生物系列II, 共两类福多司坦衍生物, 并评价了其生物活性. 结果显示, 化合物6f表现出优异的抗炎活性, IC₅₀为1.08 mmol/L, 与先导分子相比, 具有更强的抗氧化能力; 同时分子对接研究表明, 化合物6f与MUC5AC蛋白形成氢键和疏水性相互作用. 此外, 在PDE4A1酶抑制活性的试验中，发现衍生物1f的抑制作用比福多司坦高5倍. 2,2-二苯基-1-苦肼基(DPPH)自由基清除实验进一步证实, 所有受试化合物均表现出比福多司坦更强的抗氧化活性, 为进一步研究COPD药物治疗奠定了坚实的基础.

关键词: 福多司坦, 慢性阻塞性肺疾病(COPD), 胺类衍生物, 黏蛋白5AC

Chronic obstructive pulmonary disease (COPD) has garnered increased attention as a result of its persistent symptoms, which undermine patientsʼ quality of life. Fudosteine has substantial advantages in the treatment of COPD due to its high efficacy and low adverse effects. In this study, Fudosteine sulfonamide derivatives Series I and amine derivatives Series II were designed and synthesized, and their biological activities were evaluated. The results showed that compound 6f had outstanding anti-inflammatory action with an IC₅₀ of 1.08 mmol/L, and a higher antioxidant capacity than the lead molecule. At the same time, molecular docking investigations have revealed that compound 6f establishes hydrogen bonds and hydrophobic contacts with the MUC5AC protein. Furthermore, derivative 1f inhibited PDE4A1 enzyme activity five times more than Fudosteine. 2,2-Diphenyl-1-picrylhydrazyl (DPPH) free radical scavenging tests demonstrated that all examined substances had higher antioxidant activity than Fudosteine. This study established a solid foundation for further research into COPD drug therapy.

Key words: Fudosteine, chronic obstructive pulmonary disease (COPD), amine derivatives, MUC5AC

引用此文

孙茂茹, 桂腾摇, 陈聪地, 杨鸿均, 李雪锋. 慢性呼吸系统疾病药物福多司坦衍生物的设计、合成及活性评价[J]. 有机化学, 2025, 45(7): 2566-2576.

Maoru Sun, Tengyao Gui, Congdi Chen, Hongjun Yang, Xuefeng Li. Design, Synthesis, and Activity Assessment of Fudosteine Derivatives for Chronic Respiratory Disorders[J]. Chinese Journal of Organic Chemistry, 2025, 45(7): 2566-2576.

导出引用 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

分享此文

图/表 9

参考文献 29

[1]	Sahu S. K.; Rain M. D. M.; Vyas M. Eur. J. Med. Chem. Rep. 2024, 11, 100159.
[2]	Fricke-Galindo I.; Garcia-Carmona S.; Alanis-Ponce J.; Perez- Rubio G.; Ramirez-Venegas A.; Montiel-Lopez F.; Robles Her- nandez R.; Hernandez-Zenteno R. J.; Valencia-Perez Rea D.; Bautista-Becerril B.; Ramirez-Diaz M. E.; Cruz-Vicente F.; Martinez-Gomez M. L.; Sansores R.; Falfan-Valencia R. Heliyon 2024, 10, e28675.
[3]	Zeng X.; Lan Y.; Xiao J.; Hu L.; Tan L.; Liang M.; Wang X.; Lu S.; Peng T.; Long F. Expert Rev. Proteomic. 2023, 19, 311.
[4]	Yadav A. K.; Gu W.; Zhang T.; Xu X.; Yu L. COPD: J. Chronic Obstruct. Pulm. Dis. 2023, 20, 197.
[5]	Doña E.; Reinoso-Arija R.; Carrasco-Hernandez L.; Doménech A.; Dorado A.; Lopez-Campos J. L. J. Clin. Med. 2023, 12, 5293.
[6]	Durham A. L.; Adcock I. M. Lung Cancer 2015, 90, 121. doi: 10.1016/j.lungcan.2015.08.017 pmid: 26363803
[7]	Prediletto I.; Giancotti G.; Nava S. J. Clin. Med. 2023, 12, 3369.
[8]	Osoata G. O.; Hanazawa T.; Brindicci C.; Ito M.; Barnes P. J.; Kharitonov S.; Ito K. Chest 2009, 135, 1513. doi: S0012-3692(09)60355-X pmid: 19188555
[9]	Antonela Antoniu S. Expert Opin. Invest. Drug 2008, 18, 105.
[10]	Ferraro M.; Di Vincenzo S.; Sangiorgi C.; Leto Barone S.; Gangemi S.; Lanata L.; Pace E. Pharmaceuticals 2022, 15, 218.
[11]	Ueno-Iio T.; Shibakura M.; Iio K.; Tanimoto Y.; Kanehiro A.; Tanimoto M.; Kataoka M. Life Sci. 2013, 92, 1015. doi: 10.1016/j.lfs.2013.03.022 pmid: 23583570
[12]	Adeloye D.; Song P.; Zhu Y.; Campbell H.; Sheikh A.; Rudan I. Lancet Respir. Med. 2022, 10, 447. doi: 10.1016/S2213-2600(21)00511-7 pmid: 35279265
[13]	Han H.; Peng G.; Meister M.; Yao H.; Yang J. J.; Zou M.-H.; Liu Z.-R.; Ji X. Front. Pharmacol. 2021, 12, 726586.
[14]	Barnes P. J. Redox Biol. 2020, 33, 101544.
[15]	Barnes P. J. Clin. Sci. 2017, 131, 1541.
[16]	Negro R. W. D. Lung 2008, 186, 70.
[17]	Cazzola M.; Page C. P.; Wedzicha J. A.; Celli B. R.; Anzueto A.; Matera M. G. Respir. Res. 2023, 24, 194.
[18]	Barsh G. S.; Van Buren E.; Radicioni G.; Lester S.; O’Neal W. K.; Dang H.; Kasela S.; Garudadri S.; Curtis J. L.; Han M. K.; Krishnan J. A.; Wan E. S.; Silverman E. K.; Hastie A.; Ortega V. E.; Lappalainen T.; Nawijn M. C.; Berge M. v. d.; Christenson S. A.; Li Y.; Cho M. H.; Kesimer M.; Kelada S. N. P. Plos Genetics 2023, 19, e1010445.
[19]	Fu H.-T.; Zhang Y.; Zhang P.; Wu H.; Sun X.-Q.; Shen S.-Y.; Dou D.-B. Transl. Cancer Res. 2021, 10, 4047.
[20]	Radicioni G.; Ceppe A.; Ford A. A.; Alexis N. E.; Barr R. G.; Bleecker E. R.; Christenson S. A.; Cooper C. B.; Han M. K.; Hansel N. N.; Hastie A. T.; Hoffman E. A.; Kanner R. E.; Martinez F. J.; Ozkan E.; Paine R.; Woodruff P. G.; O'Neal W. K.; Boucher R. C.; Kesimer M. Lancet Respir. Med. 2021, 9, 1241. doi: 10.1016/S2213-2600(21)00079-5 pmid: 34058148
[21]	Komatsu H.; Yamaguchi S.; Komorita N.; Goto K.; Takagi S.; Ochi H.; Okumoto T. Pulm. Pharmacol. Ther. 2005, 18, 121.
[22]	Carpenter J.; Wang Y.; Gupta R.; Li Y.; Haridass P.; Subramani D. B.; Reidel B.; Morton L.; Ridley C.; O'Neal W. K.; Buisine M.-P.; Ehre C.; Thornton D. J.; Kesimer M. Proc. Natl. Acad. Sci 2021, 118, e2104490118.
[23]	Nunes J. H. B.; Nakahata D. H.; Corbi P. P.; Paiva R. E. F. D. Coord. Chem. Rev. 2023, 490, 215228.
[24]	Mahapatra M.; Mekap S. K.; Mal S.; Sahoo J.; Sahoo S. K.; Paidesetty S. K. Arch. Pharm. 2023, 356, 2200508.
[25]	Ghomashi R.; Ghomashi S.; Aghaei H.; Massah A. R. Curr. Med. Chem. 2023, 30, 407.
[26]	Whittaker H.; Rothnie K. J.; Quint J. K. Thorax 2024, 79, 202.
[27]	Rubio M. L.; Martin-Mosquero M. C.; Ortega M.; Peces-Barba G. Chest 2004, 125, 1500.
[28]	Wang Y.; Wang H.; Yang G.; Hao Q.; Yang K.; Shen H.; Wang Y.; Wang J. Eur. J. Med. Chem. 2023, 256, 115374.
[29]	Li G.; He D.; Cai X.; Guan W.; Zhang Y.; Wu J. Q.; Yao H. Eur. J. Med. Chem. 2023, 250, 115195.

Compd.	IC₅₀/(mmol•L^－1)	Compd.	IC₅₀/(mmol•L^－1)
1a	>70	6a	18.97
1b	>70	6b	39.51
1c	>70	6c	>70
1d	7.11	6d	>70
1e	5.34	6e	1.71
1f	1.05	6f	1.08
1g	11.34	6g	1.53
1h	>70	6h	1.38
1i	2.04	6i	>70
1j	8.07	6j	1.58
1k	>70	6k	>70
1l	>70	6l	>70
1m	7.02	6m	>70
1n	110.50	Fudosteine	8.43

Compd.	IC₅₀/(mmol•L^－1)	Compd.	IC₅₀/(mmol•L^－1)
1a	>70	6a	18.97
1b	>70	6b	39.51
1c	>70	6c	>70
1d	7.11	6d	>70
1e	5.34	6e	1.71
1f	1.05	6f	1.08
1g	11.34	6g	1.53
1h	>70	6h	1.38
1i	2.04	6i	>70
1j	8.07	6j	1.58
1k	>70	6k	>70
1l	>70	6l	>70
1m	7.02	6m	>70
1n	110.50	Fudosteine	8.43

Compd.	IC₅₀/(mg•mL^－1)	Compd.	IC₅₀/(mg•mL^－1)
1a	8.157	6a	2.692
1b	5.160	6c	3.473
1c	2.176	6d	4.314
1d	1.689	6e	1.910
1e	2.960	6f	0.4976
1f	1.439	6g	1.009
1g	0.320	6h	0.01264
1h	15.85	6i	0.2314
1i	3.889	6j	0.003697
1j	0.9764	6k	1.138
1k	2.137	6l	0.9286
1l	37.2	6m	0.5969
1m	6.212	Fudosteine	52.32

Compd.	IC₅₀/(mg•mL^－1)	Compd.	IC₅₀/(mg•mL^－1)
1a	8.157	6a	2.692
1b	5.160	6c	3.473
1c	2.176	6d	4.314
1d	1.689	6e	1.910
1e	2.960	6f	0.4976
1f	1.439	6g	1.009
1g	0.320	6h	0.01264
1h	15.85	6i	0.2314
1i	3.889	6j	0.003697
1j	0.9764	6k	1.138
1k	2.137	6l	0.9286
1l	37.2	6m	0.5969
1m	6.212	Fudosteine	52.32

Compd.	Inhibitory rate/%
Compd.	1 μmol•L^－1	0.1 μmol•L^－1
1a	7.08	1.93
1b	4.08	4.08
1c	3.00	2.15
1d	6.86	－1.07
1e	10.94	3.22
1f	15.44	2.15
1g	7.29	－1.29
1h	9.44	－1.29
1i	2.79	2.36
1j	3.65	2.57
1k	3.65	0.86
1l	7.94	0
1m	2.57	－1.50
Fudosteine	3.65	8.58

慢性呼吸系统疾病药物福多司坦衍生物的设计、合成及活性评价

Design, Synthesis, and Activity Assessment of Fudosteine Derivatives for Chronic Respiratory Disorders

RichHTML

PDF

补充材料

可视化

摘要/Abstract

引用此文

分享此文

图/表 9

参考文献 29

相关文章 4

编辑推荐

相关统计

本文评价

[1]	李琳琳, 陈晓雨, 裴聪聪, 李敬亚, 邹大鹏, 吴养洁, 吴豫生. 无金属条件下叔丁基亚磺酰胺衍生物在B₂pin₂/D₂O体系中的氘代还原[J]. 有机化学, 2021, 41(6): 2319-2325.
[2]	华迎春, 贺斌, 秦之焱, 王松, 刘慧萍, 刘丰五. 吗啉核苷类似物及其磺胺衍生物的合成及初步抗牛病毒性腹泻病毒(BVDV)活性研究[J]. 有机化学, 2018, 38(5): 1147-1154.
[3]	陈翠, 徐松森, 刘卫兵. 硼氢化钠选择性还原乙酰乙酰苯胺至不饱和烯胺和β-羟基酰胺[J]. 有机化学, 2016, 36(8): 1890-1894.
[4]	蔡谊敏,高祥,黄现统,王统建,赵玉芬. 磷酰化氨基酸酯的合成、波谱表征及生物活性[J]. 有机化学, 2006, 26(12): 1677-1681.